Pliant Therapeutics Changes Fiscal Year End

TL;DR

Pliant Therapeutics is shifting its fiscal year end to September 30, starting now.

AI Summary

Pliant Therapeutics, Inc. filed an 8-K on September 27, 2024, reporting a change in its fiscal year end from December 31 to September 30, effective September 24, 2024. This change will impact the timing of their financial reporting periods going forward.

Why It Matters

This change in fiscal year end will alter the company's financial reporting calendar, potentially affecting the timing of earnings releases and investor communications.

Risk Assessment

Risk Level: low — A change in fiscal year end is a routine administrative change with no immediate financial or operational impact.

Key Players & Entities

• PLIANT THERAPEUTICS, INC. (company) — Registrant
• September 24, 2024 (date) — Effective date of fiscal year change
• September 30 (date) — New fiscal year end
• December 31 (date) — Previous fiscal year end

FAQ

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 per share PLRX The Nasdaq Stock Market

Filing Documents

• plrx-20240924.htm (8-K) — 30KB
• plrx-thirdamendedandrestat.htm (EX-3.1) — 302KB
• 0001746473-24-000153.txt ( ) — 495KB
• plrx-20240924.xsd (EX-101.SCH) — 2KB
• plrx-20240924_lab.xml (EX-101.LAB) — 22KB
• plrx-20240924_pre.xml (EX-101.PRE) — 13KB
• plrx-20240924_htm.xml (XML) — 3KB

03 Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year

Item 5.03 Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year. On September 24, 2024, the Board of Directors of Pliant Therapeutics, Inc. (the "Company") approved the amendment and restatement of the Bylaws of the Company (as so amended and restated, the "Third Amended and Restated Bylaws"). The Third Amended and Restated Bylaws are effective as of September 24, 2024. The amendments effected by the Third Amended and Restated Bylaws, among other things: (i) align the Company's bylaws with developments in Delaware law and jurisprudence; (ii) revise the procedural and disclosure requirements applicable to stockholders' director nominations and proposals for other business; and (iii) include a provision regarding severability. The Third Amended and Restated Bylaws also implement certain other ministerial and conforming changes. The foregoing description does not purport to be complete and is qualified in its entirety by the complete text of the Third Amended and Restated Bylaws, a copy of which is filed herewith as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 3.1 Third Amended and Restated Bylaws, effective September 24, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. PLIANT THERAPEUTICS, INC. Date: September 27, 2024 By: /s/ Keith Cummings Keith Cummings, M.D., MBA Chief Financial Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR